<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02587650</url>
  </required_header>
  <id_info>
    <org_study_id>14859</org_study_id>
    <secondary_id>NCI-2017-01421</secondary_id>
    <nct_id>NCT02587650</nct_id>
  </id_info>
  <brief_title>Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma</brief_title>
  <official_title>A Phase II Trial of Targeted Kinase Fusion Inhibition in Unresectable Stage III/IV BRAF/NRAS Wild-Type Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies how well capmatinib, ceritinib, regorafenib, or entrectinib work&#xD;
      in treating patients with BRAF/NRAS wild-type stage III-IV melanoma. Capmatinib, ceritinib,&#xD;
      regorafenib, or entrectinib may stop the growth of tumor cells by blocking some of the&#xD;
      enzymes needed for cell growth.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To estimate the clinical activity of tyrosine kinase inhibitors matched to the&#xD;
      tumor-specific fusion kinase in patients with metastatic melanoma.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To estimate tumor stability in melanoma patients treated with kinase inhibitors matched to&#xD;
      the tumor-specific fusion kinase.&#xD;
&#xD;
      II. To estimate survival in melanoma patients treated with kinase inhibitors matched to the&#xD;
      tumor-specific fusion kinase.&#xD;
&#xD;
      III. To examine the safety and tolerability of kinase inhibitors in patients with melanoma&#xD;
      with a fusion kinase.&#xD;
&#xD;
      TERTIARY OBJECTIVES:&#xD;
&#xD;
      I. To explore molecular mechanisms of resistance for patients who progress on therapy.&#xD;
&#xD;
      OUTLINE: Patients are assigned to 1 of 4 arms.&#xD;
&#xD;
      ARM A: Patients with MET fusion receive capmatinib orally (PO) twice daily (BID) on day 1-28.&#xD;
      Courses repeat every 28 days in the absence of disease progression or unaccepted toxicity.&#xD;
&#xD;
      ARM B: Patients with ALK fusion receive ceritinib PO once daily (QD) on days 1-28. Courses&#xD;
      repeat every 28 days in the absence of disease progression or unaccepted toxicity.&#xD;
&#xD;
      ARM C: Patients with RET or BRAF fusion receive regorafenib PO QD on day 1-21. Courses repeat&#xD;
      every 28 days in the absence of disease progression or unaccepted toxicity.&#xD;
&#xD;
      ARM D: Patients with NTRK1, NTRK2, NTRK3, or ROS1 fusion receive entrectinib PO QD on days&#xD;
      1-28. Courses repeat every 28 days in the absence of disease progression or unaccepted&#xD;
      toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed up within 30 days and then&#xD;
      periodically.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Funding&#xD;
  </why_stopped>
  <start_date type="Actual">March 26, 2015</start_date>
  <completion_date type="Actual">July 12, 2018</completion_date>
  <primary_completion_date type="Actual">July 12, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Confirmed Overall Response Rate (ORR)</measure>
    <time_frame>24 weeks</time_frame>
    <description>Defined as a complete or partial response as per Response Evaluation Criteria in Solid Tumors version 1.1 criteria with confirmatory measurements a minimum of 4 weeks after the response-defining determination. Analysis of study results will include ORR estimations of ALK, NTRK, ROS1, RET, MET, and BRAF rearrangement-positive patients.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Benefit Rate (CBR)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Clinical benefit rate is defined as the proportion of patients achieving a complete response (CR) or partial response (PR) or stable disease (SD) for &gt; 24 weeks using the same RECIST 1.1 decision matrix used to calculate ORR. The CBR will be estimated for each arm along with a 95% confidence interval</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>From treatment start to death, assessed up to 2 years</time_frame>
    <description>Overall defined as the time from treatment start to the progression or death and overall survival defined as the time from treatment start to death will be estimated using Kaplan-Meier methodology.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Progression free survival (PFS) defined as the time from treatment start to the progression or death and overall survival defined as the time from treatment start to death will be estimated using Kaplan-Meier methodology</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the Adverse Effect Profile of Each Kinase Inhibitor</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Frequencies of toxicities will be tabulated according to CTCAE v4.03 to assess drug safety and tolerability</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>ALK Fusion Protein Expression</condition>
  <condition>BRAF wt Allele</condition>
  <condition>Invasive Skin Melanoma</condition>
  <condition>MET Fusion Gene Positive</condition>
  <condition>NRAS wt Allele</condition>
  <condition>NTRK1 Fusion Positive</condition>
  <condition>NTRK2 Fusion Positive</condition>
  <condition>NTRK3 Fusion Positive</condition>
  <condition>RET Fusion Positive</condition>
  <condition>ROS1 Fusion Positive</condition>
  <condition>Stage III Cutaneous Melanoma</condition>
  <condition>Stage IIIA Cutaneous Melanoma</condition>
  <condition>Stage IIIB Cutaneous Melanoma</condition>
  <condition>Stage IIIC Cutaneous Melanoma</condition>
  <condition>Stage IV Cutaneous Melanoma</condition>
  <arm_group>
    <arm_group_label>Arm A (capmatinib)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with MET fusion receive capmatinib PO BID on day 1-28. Courses repeat every 28 days in the absence of disease progression or unaccepted toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B (ceritinib)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with ALK fusion receive ceritinib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unaccepted toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C (regorafenib)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with RET or BRAF fusion receive regorafenib PO QD on day 1-21. Courses repeat every 28 days in the absence of disease progression or unaccepted toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm D (entrectinib)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with NTRK1, NTRK2, NTRK3, OR ROS1 fusion receive entrectinib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unaccepted toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capmatinib</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm A (capmatinib)</arm_group_label>
    <other_name>INC-280</other_name>
    <other_name>INC280</other_name>
    <other_name>INCB 28060</other_name>
    <other_name>INCB028060</other_name>
    <other_name>INCB28060</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ceritinib</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm B (ceritinib)</arm_group_label>
    <other_name>LDK 378</other_name>
    <other_name>LDK378</other_name>
    <other_name>Zykadia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Entrectinib</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm D (entrectinib)</arm_group_label>
    <other_name>RXDX-101</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm A (capmatinib)</arm_group_label>
    <arm_group_label>Arm B (ceritinib)</arm_group_label>
    <arm_group_label>Arm C (regorafenib)</arm_group_label>
    <arm_group_label>Arm D (entrectinib)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Regorafenib</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm C (regorafenib)</arm_group_label>
    <other_name>BAY 73-4506</other_name>
    <other_name>Stivarga</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  CAPMATINIB INCLUSION CRITERIA:&#xD;
&#xD;
               -  Ability to understand a written informed consent document, and the willingness to&#xD;
                  sign it&#xD;
&#xD;
               -  Eastern Cooperative Oncology Group (ECOG) performance status 0-1&#xD;
&#xD;
               -  Life expectancy &gt;= 12 weeks&#xD;
&#xD;
               -  Histologically or cytologically confirmed invasive melanoma&#xD;
&#xD;
               -  Unresectable stage III or stage IV melanoma by clinical or radiographic criteria&#xD;
&#xD;
               -  Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST)&#xD;
                  version (v)1.1&#xD;
&#xD;
               -  Documentation of absence of activating and targetable BRAF or NRAS point&#xD;
                  mutations&#xD;
&#xD;
               -  Presence of an oncogenic kinase fusion involving MET, confirmed by assay by a&#xD;
                  Clinical Laboratory Improvement Act (CLIA)-approved laboratory&#xD;
&#xD;
               -  Prior treatment with at least one Food and Drug Administration (FDA)-approved&#xD;
                  drug for unresectable/metastatic melanoma; patients who are treatment-naive but&#xD;
                  who refuse available standard options and prefer to enroll on this study as their&#xD;
                  first line of treatment after a thorough informed consent process will be&#xD;
                  eligible at the discretion of the treating physician&#xD;
&#xD;
               -  Resolution of all acute toxic effects (excluding alopecia) of prior radiotherapy,&#xD;
                  chemotherapy or surgical procedures to Common Terminology Criteria for Adverse&#xD;
                  Events (CTCAE) v4.03 grade =&lt; 1&#xD;
&#xD;
               -  Absolute neutrophil count &gt;= 1,500/mm^3&#xD;
&#xD;
               -  Platelets &gt;= 75,000/ microliters (mcL)&#xD;
&#xD;
               -  Hemoglobin &gt;= 9 g/dL (transfusions are allowed)&#xD;
&#xD;
               -  Total bilirubin =&lt; 1.5 x upper limit of normal (ULN); patients with Gilbert?s&#xD;
                  syndrome may be included if total bilirubin =&lt; 3 x ULN or direct bilirubin =&lt; 1.5&#xD;
                  x ULN&#xD;
&#xD;
               -  Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT])&#xD;
                  and alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT])&#xD;
                  =&lt; 3 x ULN if no liver metastases are present? =&lt; 5 x ULN if liver metastases are&#xD;
                  present&#xD;
&#xD;
               -  Alkaline phosphatase (ALP) =&lt; 5 x ULN&#xD;
&#xD;
               -  Serum amylase =&lt; grade 2 and asymptomatic; patients with grade 1 or 2 serum&#xD;
                  amylase at the beginning of the study must be confirmed to have no signs and/or&#xD;
                  symptoms suggesting pancreatitis or pancreatic injury (e.g., elevated P-amylase,&#xD;
                  abnormal imaging findings of pancreas, etc.)&#xD;
&#xD;
               -  Serum lipase =&lt; ULN&#xD;
&#xD;
               -  Creatinine OR creatinine clearance within normal limits &gt; 40 mL/min (calculated&#xD;
                  by Cockgraft-Gault) for patients with creatinine levels above ULN&#xD;
&#xD;
               -  Serum potassium, calcium (corrected for serum albumin), magnesium, phosphorus&#xD;
                  within normal limits with or without supplementation&#xD;
&#xD;
          -  CERITINIB INCLUSION CRITERIA:&#xD;
&#xD;
               -  Ability to understand a written informed consent document, and the willingness to&#xD;
                  sign it&#xD;
&#xD;
               -  ECOG performance status 0-1&#xD;
&#xD;
               -  Life expectancy &gt;= 12 weeks&#xD;
&#xD;
               -  Histologically or cytologically confirmed invasive melanoma&#xD;
&#xD;
               -  Unresectable stage III or stage IV melanoma by clinical or radiographic criteria&#xD;
&#xD;
               -  Measurable disease by RECIST v1.1&#xD;
&#xD;
               -  Documentation of absence of activating and targetable BRAF or NRAS point&#xD;
                  mutations&#xD;
&#xD;
               -  Presence of an oncogenic kinase fusion involving ALK, confirmed by assay by a&#xD;
                  CLIA-approved laboratory&#xD;
&#xD;
               -  Prior treatment with at least one FDA-approved drug for unresectable/metastatic&#xD;
                  melanoma; patients who are treatment-naive but who refuse available standard&#xD;
                  options and prefer to enroll on this study as their first line of treatment after&#xD;
                  a thorough informed consent process will be eligible at the discretion of the&#xD;
                  treating physician&#xD;
&#xD;
               -  Resolution of all acute toxic effects (excluding alopecia) of prior radiotherapy,&#xD;
                  chemotherapy or surgical procedures to CTCAE v4.03 grade =&lt; 1&#xD;
&#xD;
               -  Absolute neutrophil count &gt;= 1.5 x 10^9/L&#xD;
&#xD;
               -  Platelets &gt;= 75 x 10^9/L&#xD;
&#xD;
               -  Hemoglobin &gt;= 8 g/dL (transfusions are allowed)&#xD;
&#xD;
               -  Total bilirubin =&lt; 1.5 x upper limit of normal (ULN); patients with Gilbert?s&#xD;
                  syndrome may be included if total bilirubin =&lt; 3 x ULN and direct bilirubin =&lt;&#xD;
                  1.5 x ULN&#xD;
&#xD;
               -  AST (SGOT) and ALT (SGPT) =&lt; 3 x ULN if no liver metastases are present? =&lt; 5 x&#xD;
                  ULN if liver metastases are present&#xD;
&#xD;
               -  Alkaline phosphatase (ALP) =&lt; 5 x ULN&#xD;
&#xD;
               -  Serum amylase =&lt; 2 x ULN&#xD;
&#xD;
               -  Serum lipase =&lt; ULN&#xD;
&#xD;
               -  Fasting plasma glucose =&lt; 175 mg/dL (=&lt; 9.8 mmol/L)&#xD;
&#xD;
               -  Creatinine OR creatinine clearance &lt; 1.5 mg/dL &gt;= 30 mL/min (calculated by&#xD;
                  Cockgraft-Gault) for patients with creatinine levels above ULN&#xD;
&#xD;
               -  Serum potassium, calcium (corrected for serum albumin), magnesium, phosphorus&#xD;
                  within normal limits with or without supplementation&#xD;
&#xD;
          -  REGORAFENIB INCLUSION CRITERIA:&#xD;
&#xD;
               -  Ability to understand a written informed consent document, and the willingness to&#xD;
                  sign it&#xD;
&#xD;
               -  ECOG performance status 0-1&#xD;
&#xD;
               -  Life expectancy &gt;= 12 weeks&#xD;
&#xD;
               -  Histologically or cytologically confirmed invasive melanoma&#xD;
&#xD;
               -  Unresectable stage III or stage IV melanoma by clinical or radiographic criteria&#xD;
&#xD;
               -  Measurable disease by RECIST v1.1&#xD;
&#xD;
               -  Documentation of absence of activating and targetable BRAF or NRAS point&#xD;
                  mutations&#xD;
&#xD;
               -  Presence of an oncogenic kinase fusion involving BRAF or RET, confirmed by assay&#xD;
                  by a CLIA-approved laboratory&#xD;
&#xD;
               -  Prior treatment with at least one FDA-approved drug for unresectable/metastatic&#xD;
                  melanoma; patients who are treatment-naive but who refuse available standard&#xD;
                  options and prefer to enroll on this study as their first line of treatment after&#xD;
                  a thorough informed consent process will be eligible at the discretion of the&#xD;
                  treating physician&#xD;
&#xD;
               -  Resolution of all acute toxic effects (excluding alopecia) of prior radiotherapy,&#xD;
                  chemotherapy or surgical procedures to CTCAE v4.03 grade =&lt; 1&#xD;
&#xD;
               -  Absolute neutrophil count &gt;= 1,500/mm^3&#xD;
&#xD;
               -  Platelets &gt;= 100,000/mm^3&#xD;
&#xD;
               -  Hemoglobin &gt;= 9 g/dL&#xD;
&#xD;
               -  Total bilirubin =&lt; 1.5 x upper limit of normal (ULN); patients with Gilbert?s&#xD;
                  syndrome may be included if total bilirubin =&lt; 3 x ULN or direct bilirubin =&lt; 1.5&#xD;
                  x ULN&#xD;
&#xD;
               -  AST (SGOT) and ALT (SGPT) =&lt; 2.5 x ULN if no liver metastases are present? =&lt; 5 x&#xD;
                  ULN if liver metastases are present&#xD;
&#xD;
               -  Alkaline phosphatase (ALP) =&lt; 2.5 x ULN if no liver metastases are present; =&lt; 5&#xD;
                  x ULN if bone or liver metastases are present&#xD;
&#xD;
               -  Creatinine OR creatinine clearance =&lt; 1.5 x ULN; &gt; 40 mL/min (calculated by&#xD;
                  Cockgraft-Gault) for patients with creatinine levels above ULN&#xD;
&#xD;
               -  Serum potassium, calcium (corrected for serum albumin), magnesium, phosphorus&#xD;
                  within normal limits with or without supplementation&#xD;
&#xD;
               -  International normalized ratio (INR) and partial thromboplastin time (PTT) =&lt; 1.5&#xD;
                  x ULN (patients who are prophylactically treated with an agent such as warfarin&#xD;
                  or heparin will be allowed to participate, provided that no prior evidence of&#xD;
                  underlying abnormality in coagulation parameters exists; close monitoring of at&#xD;
                  least weekly evaluations will be performed until INR/PTT is stable based on a&#xD;
                  measurement that is predose as defined by the local standard of care)&#xD;
&#xD;
          -  ENTRECTINIB INCLUSION CRITERIA:&#xD;
&#xD;
               -  Ability to understand a written informed consent document, and the willingness to&#xD;
                  sign it&#xD;
&#xD;
               -  ECOG performance status 0-2&#xD;
&#xD;
               -  Histologically or cytologically confirmed invasive melanoma&#xD;
&#xD;
               -  Unresectable stage III or stage IV melanoma by clinical or radiographic criteria&#xD;
&#xD;
               -  Measurable disease by RECIST v1.1&#xD;
&#xD;
               -  Patients with central nervous system (CNS) involvement, including leptomeningeal&#xD;
                  carcinomatosis, which is either asymptomatic or previously-treated and&#xD;
                  controlled, are allowed; the use of seizure prophylaxis is allowed as long as&#xD;
                  patients are taking non enzyme-inducing anti-epileptic drugs (non-EIAEDs); if&#xD;
                  patients were previously on EIAEDs and these have been discontinued, they must&#xD;
                  have been discontinued for at least 2 weeks prior to the start of entrectinib&#xD;
                  treatment; if patients require an anti-epileptic medication, a CYP3A4 non-EIAED&#xD;
                  can be used such as levetiracetam, valproic acid, gabapentin, topiramate, or&#xD;
                  lacosamide; moderate inducers of CYP450, such as dexamethasone or other&#xD;
                  glucocorticoids, may be used at the discretion of the investigator; patients&#xD;
                  requiring steroids must be at a stable or decreasing doses for at least 2 weeks&#xD;
                  prior to the start of entrectinib treatment&#xD;
&#xD;
               -  Documentation of absence of activating and targetable BRAF or NRAS point&#xD;
                  mutations&#xD;
&#xD;
               -  Presence of an oncogenic kinase fusion involving ROS1 or NTRK1/2/3, confirmed by&#xD;
                  assay by a CLIA-approved laboratory&#xD;
&#xD;
               -  Prior treatment with at least one FDA-approved drug for unresectable/metastatic&#xD;
                  melanoma; patients who are treatment-naive but who refuse available standard&#xD;
                  options and prefer to enroll on this study as their first line of treatment after&#xD;
                  a thorough informed consent process will be eligible at the discretion of the&#xD;
                  treating physician&#xD;
&#xD;
               -  Resolution of all acute toxic effects (excluding alopecia) of prior radiotherapy,&#xD;
                  chemotherapy or surgical procedures to CTCAE v4.03 grade =&lt; 1&#xD;
&#xD;
               -  Absolute neutrophil count &gt;= 1,000/mm^3&#xD;
&#xD;
               -  Platelets &gt;= 75,000/mcL&#xD;
&#xD;
               -  Hemoglobin &gt;= 8 g/dL (transfusions are allowed)&#xD;
&#xD;
               -  Total bilirubin =&lt; 1.5 x upper limit of normal (ULN); patients with Gilbert?s&#xD;
                  syndrome may be included if total bilirubin =&lt; 3 x ULN or direct bilirubin =&lt; 1.5&#xD;
                  x ULN&#xD;
&#xD;
               -  AST (SGOT) and ALT (SGPT) =&lt; 3.0 x ULN if no liver metastases are present? =&lt; 5 x&#xD;
                  ULN if liver metastases are present&#xD;
&#xD;
               -  Creatinine OR creatinine clearance within normal limits; &gt; 40 mL/min (calculated&#xD;
                  by Cockgraft-Gault) for patients with creatinine levels above ULN&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  CAPMATINIB EXCLUSION CRITERIA: Uveal melanoma&#xD;
&#xD;
          -  CAPMATINIB EXCLUSION CRITERIA: Current participation in another therapeutic clinical&#xD;
             trial&#xD;
&#xD;
          -  CAPMATINIB EXCLUSION CRITERIA: Inability to swallow intact tablets or capsules&#xD;
&#xD;
          -  CAPMATINIB EXCLUSION CRITERIA: Previously identified allergy or hypersensitivity to&#xD;
             components of capmatinib formulation (crospovidone, mannitol, microcrystalline&#xD;
             cellulose, povidone, sodium lauryl sulfate, magnesium stearate, colloidal silicon&#xD;
             dioxide, and various coating premixes)&#xD;
&#xD;
          -  CAPMATINIB EXCLUSION CRITERIA: Diagnosis of concurrent malignancy or previous&#xD;
             malignancy within 3 years before study drug administration (exceptions are superficial&#xD;
             skin cancers, or any in situ cancers deemed surgically resected, cured and not&#xD;
             requiring systemic therapy, and indolent malignancies that currently do not require&#xD;
             treatment)&#xD;
&#xD;
          -  CAPMATINIB EXCLUSION CRITERIA: Prior treatment with the following antineoplastic&#xD;
             therapies within the following time frame:&#xD;
&#xD;
               -  Any prior treatment with capmatinib, crizotinib, or any other cMET or hepatocyte&#xD;
                  growth factor (HGF) inhibitor&#xD;
&#xD;
               -  Thoracic radiotherapy to lung fields =&lt; 4 weeks prior to starting capmatinib; for&#xD;
                  all other anatomic sites (including radiotherapy to thoracic vertebrae and ribs),&#xD;
                  radiotherapy =&lt; 2 weeks prior to starting capmatinib; palliative radiotherapy for&#xD;
                  bone lesions =&lt; 2 weeks prior to starting capmatinib is allowed&#xD;
&#xD;
               -  Receipt of any anticancer or investigational agent within 4 weeks or =&lt; 5&#xD;
                  half-lives of the agent (whichever is longer) prior to the first dose of&#xD;
                  capmatinib; if previous treatment is a monoclonal antibody, then the treatment&#xD;
                  must be discontinued at least 4 weeks before the first dose of capmatinib&#xD;
&#xD;
          -  CAPMATINIB EXCLUSION CRITERIA: Major surgery (e.g., intrathoracic, intraabdominal or&#xD;
             intrapelvic) within 4 weeks prior (2 weeks for resection of brain metastases) to&#xD;
             starting capmatinib; video-assisted thoracic surgery (VATS) and mediastinoscopy will&#xD;
             not be counted as major surgery and patients can be enrolled in the study &gt;= 1 week&#xD;
             after the procedure&#xD;
&#xD;
          -  CAPMATINIB EXCLUSION CRITERIA: Patients receiving treatment with medications that meet&#xD;
             one of the following criteria and that cannot be discontinued at least 1 week prior to&#xD;
             the start of capmatinib treatment and for the duration of the study:&#xD;
&#xD;
               -  Strong and moderate inhibitors of CYP3A4&#xD;
&#xD;
               -  Strong inducers of CYP3A4&#xD;
&#xD;
               -  Proton pump inhibitors (PPI)&#xD;
&#xD;
          -  CAPMATINIB EXCLUSION CRITERIA: Patients on unstable or increasing doses of&#xD;
             corticosteroids; if patients are on corticosteroids for endocrine deficiencies or&#xD;
             tumor-associated symptoms other than CNS related, dose must have been stabilized or&#xD;
             decreasing for at least 5 days before first dose of capmatinib&#xD;
&#xD;
          -  CAPMATINIB EXCLUSION CRITERIA: Presence or history of carcinomatous meningitis&#xD;
&#xD;
          -  CAPMATINIB EXCLUSION CRITERIA: Known symptomatic brain metastases requiring increasing&#xD;
             doses of steroid to manage CNS symptoms within 2 weeks prior to study entry&#xD;
&#xD;
               -  Patients with asymptomatic brain metastases may be enrolled at the discretion of&#xD;
                  the sponsor as long as the patient is stable and has not required increasing dose&#xD;
                  of steroids to manage CNS symptoms for at least 2 weeks prior to study enrollment&#xD;
&#xD;
               -  Patients requiring seizure prophylaxis must be taking non-enzyme-inducing&#xD;
                  anti-epileptic drugs (non-EIAED); if patients were previously on EIAEDs and these&#xD;
                  have been discontinued, they must be discontinued for at least 1 weeks prior to&#xD;
                  capmatinib administration; if patients re&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adil Daud</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>October 23, 2015</study_first_submitted>
  <study_first_submitted_qc>October 26, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 27, 2015</study_first_posted>
  <results_first_submitted>October 17, 2019</results_first_submitted>
  <results_first_submitted_qc>January 14, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">January 27, 2020</results_first_posted>
  <last_update_submitted>January 14, 2020</last_update_submitted>
  <last_update_submitted_qc>January 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Francisco</investigator_affiliation>
    <investigator_full_name>Adil Daud</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Skin Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ceritinib</mesh_term>
    <mesh_term>Entrectinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 20, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/50/NCT02587650/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 22, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/50/NCT02587650/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Arm A (Capmatinib)</title>
          <description>Patients with MET fusion receive capmatinib orally (PO), twice a day (BID) on day 1-28. Courses repeat every 28 days in the absence of disease progression or unaccepted toxicity.&#xD;
Capmatinib: Given orally&#xD;
Laboratory Biomarker Analysis: Correlative studies</description>
        </group>
        <group group_id="P2">
          <title>Arm B (Ceritinib)</title>
          <description>Patients with ALK fusion receive ceritinib PO once a day (QD) on days 1-28. Courses repeat every 28 days in the absence of disease progression or unaccepted toxicity.&#xD;
Ceritinib: Given PO&#xD;
Laboratory Biomarker Analysis: Correlative studies</description>
        </group>
        <group group_id="P3">
          <title>Arm C (Regorafenib)</title>
          <description>Patients with RET or BRAF fusion receive regorafenib PO QD on day 1-21. Courses repeat every 28 days in the absence of disease progression or unaccepted toxicity.&#xD;
Laboratory Biomarker Analysis: Correlative studies&#xD;
Regorafenib: Given PO</description>
        </group>
        <group group_id="P4">
          <title>Arm D (Entrectinib)</title>
          <description>Patients with NTRK1, NTRK2, NTRK3, OR ROS1 fusion receive entrectinib PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unaccepted toxicity.&#xD;
Entrectinib: Given PO&#xD;
Laboratory Biomarker Analysis: Correlative studies</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Only 1 participant was enrolled on this protocol to Arm C (regorafenib). Evaluable patients would be those with baseline staging, treatment for at least 8 weeks, and at least one post-baseline staging scan while on treatment. No participants meet the criteria to be considered evaluable for this protocol.</population>
      <group_list>
        <group group_id="B1">
          <title>Arm C (Regorafenib)</title>
          <description>Participants with RET or BRAF mutations</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>60-65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Confirmed Overall Response Rate (ORR)</title>
        <description>Defined as a complete or partial response as per Response Evaluation Criteria in Solid Tumors version 1.1 criteria with confirmatory measurements a minimum of 4 weeks after the response-defining determination. Analysis of study results will include ORR estimations of ALK, NTRK, ROS1, RET, MET, and BRAF rearrangement-positive patients.</description>
        <time_frame>24 weeks</time_frame>
        <population>Evaluable participants would be those with baseline staging, treatment for at least 8 weeks, and at least one post-baseline staging scan while on treatment. No participants meet the criteria to be considered evaluable for this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm C (Regorafenib)</title>
            <description>Patients with RET or BRAF mutations</description>
          </group>
        </group_list>
        <measure>
          <title>Confirmed Overall Response Rate (ORR)</title>
          <description>Defined as a complete or partial response as per Response Evaluation Criteria in Solid Tumors version 1.1 criteria with confirmatory measurements a minimum of 4 weeks after the response-defining determination. Analysis of study results will include ORR estimations of ALK, NTRK, ROS1, RET, MET, and BRAF rearrangement-positive patients.</description>
          <population>Evaluable participants would be those with baseline staging, treatment for at least 8 weeks, and at least one post-baseline staging scan while on treatment. No participants meet the criteria to be considered evaluable for this analysis.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Benefit Rate (CBR)</title>
        <description>Clinical benefit rate is defined as the proportion of patients achieving a complete response (CR) or partial response (PR) or stable disease (SD) for &gt; 24 weeks using the same RECIST 1.1 decision matrix used to calculate ORR. The CBR will be estimated for each arm along with a 95% confidence interval</description>
        <time_frame>Up to 2 years</time_frame>
        <population>Evaluable patients would be those with baseline staging, treatment for at least 8 weeks, and at least one post-baseline staging scan while on treatment. No participants meet the criteria to be considered evaluable for this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm C (Regorafenib)</title>
            <description>Patients with RET or BRAF mutations</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Benefit Rate (CBR)</title>
          <description>Clinical benefit rate is defined as the proportion of patients achieving a complete response (CR) or partial response (PR) or stable disease (SD) for &gt; 24 weeks using the same RECIST 1.1 decision matrix used to calculate ORR. The CBR will be estimated for each arm along with a 95% confidence interval</description>
          <population>Evaluable patients would be those with baseline staging, treatment for at least 8 weeks, and at least one post-baseline staging scan while on treatment. No participants meet the criteria to be considered evaluable for this analysis.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>Overall defined as the time from treatment start to the progression or death and overall survival defined as the time from treatment start to death will be estimated using Kaplan-Meier methodology.</description>
        <time_frame>From treatment start to death, assessed up to 2 years</time_frame>
        <population>Evaluable patients would be those with baseline staging, treatment for at least 8 weeks, and at least one post-baseline staging scan while on treatment. No participants meet the criteria to be considered evaluable for this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm C (Regorafenib)</title>
            <description>Patients with RET or BRAF mutations</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>Overall defined as the time from treatment start to the progression or death and overall survival defined as the time from treatment start to death will be estimated using Kaplan-Meier methodology.</description>
          <population>Evaluable patients would be those with baseline staging, treatment for at least 8 weeks, and at least one post-baseline staging scan while on treatment. No participants meet the criteria to be considered evaluable for this analysis.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression Free Survival</title>
        <description>Progression free survival (PFS) defined as the time from treatment start to the progression or death and overall survival defined as the time from treatment start to death will be estimated using Kaplan-Meier methodology</description>
        <time_frame>up to 2 years</time_frame>
        <population>Evaluable patients would be those with baseline staging, treatment for at least 8 weeks, and at least one post-baseline staging scan while on treatment. No participants meet the criteria to be considered evaluable for this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm C (Regorafenib)</title>
            <description>Patients with RET or BRAF mutations</description>
          </group>
        </group_list>
        <measure>
          <title>Progression Free Survival</title>
          <description>Progression free survival (PFS) defined as the time from treatment start to the progression or death and overall survival defined as the time from treatment start to death will be estimated using Kaplan-Meier methodology</description>
          <population>Evaluable patients would be those with baseline staging, treatment for at least 8 weeks, and at least one post-baseline staging scan while on treatment. No participants meet the criteria to be considered evaluable for this analysis.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evaluation of the Adverse Effect Profile of Each Kinase Inhibitor</title>
        <description>Frequencies of toxicities will be tabulated according to CTCAE v4.03 to assess drug safety and tolerability</description>
        <time_frame>Up to 2 years</time_frame>
        <population>Evaluable patients would be those with baseline staging, treatment for at least 8 weeks, and at least one post-baseline staging scan while on treatment. No participants meet the criteria to be considered evaluable for this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm C (Regorafenib)</title>
            <description>Patients with RET or BRAF mutations</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluation of the Adverse Effect Profile of Each Kinase Inhibitor</title>
          <description>Frequencies of toxicities will be tabulated according to CTCAE v4.03 to assess drug safety and tolerability</description>
          <population>Evaluable patients would be those with baseline staging, treatment for at least 8 weeks, and at least one post-baseline staging scan while on treatment. No participants meet the criteria to be considered evaluable for this analysis.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 3 months</time_frame>
      <desc>Analyses will be performed for all participants having received at least one dose of study drug. Only one participant was enrolled on this trial to Arm C (Regorafenib) for a total of 3 months. Adverse Events reported are for single accrued participant</desc>
      <group_list>
        <group group_id="E1">
          <title>Arm C (Regorafenib)</title>
          <description>Patients with RET or BRAF mutations</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flashes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Only 1 participant was enrolled on this study to Arm C (regorafenib) based on the participants mutation profile. The study was terminated after one accrual due to lack of funding.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Adil Daud</name_or_title>
      <organization>University of California, San Francisco</organization>
      <phone>(415) 353-7392</phone>
      <email>Adil.Daud@ucsf.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

